ela

We live in a society where we’ve learned to assume that newer is always better. If a smartphone is newer, we assume it’s faster. If a software update rolls out, we assume the bugs are fixed. And when that same logic carries over into medicine, it feels completely natural. When we hear about a "cutting-edge" medical treatment, our instinct is to believe it must be vastly superior to the traditional options. However, that assumption can actually be quite dangerous. Like Neurofeedback. It is a modern, noninvasive technique designed to train the brain and improve self-regulation, and it is often promoted as a promising tool for mental health treatment. However, neurofeedback should not be considered a primary treatment for mental health disorders, but rather a complementary tool. In irregularity i n result outcomes According to the ADHD Evidence Project, Faraone conducted a meta-analysis of 17 randomized controlled trials that found that neurofeedback produced no significant improvement in ADHD symptoms, with results essentially centered around zero. And that matters because a primary mental health treatment has to consistently demonstrate real, measurable improvement across strong scientific evidence. This source suggests that neurofeedback’s effects are inconsistent at best, which means it does not meet the standard required for a primary treatment in mental health care and proves that neurofeedback, despite the high-tech appeal, simply does not meet the strict standard required to be a primary treatment. But the issue goes beyond inconsistent results—it also raises a bigger question: why do some people still report improvement? Thibault, in his article “Neurofeedback or Neuroplacebo?”, explains that in well-controlled studies, sham neurofeedback often produces results similar to genuine neurofeedback, suggesting that placebo-like effects and patient expectations may play a significant role in perceived improvement. And that’s critical, because neurofeedback is marketed as a treatment that directly trains brain activity through feedback loops, implying actual neurological change. But when similar outcomes occur even without genuine feedback, it begins to resemble something that may create short-term optimism or perceived progress without consistently addressing the underlying condition. And that shift matters because if patients believe they are receiving a scientifically advanced treatment but fail to see lasting improvement, they may begin to internalize that lack of progress as a personal failure rather than recognizing the limitations of the treatment itself.